FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                       
1. Name and Address of Reporting Person * Taylor Stacy L 2. Issuer Name and Ticker or Trading Symbol Adaptive Biotechnologies Corp [ ADPT ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
SVP and General Counsel
(Last)         (First)         (Middle)
C/O ADAPTIVE BIOTECHNOLOGIES, 1551 EASTLAKE AVE E STE 200		 3. Date of Earliest Transaction (MM/DD/YYYY)
10/26/2020
(Street)
SEATTLE, WA 98102
(City)       (State)       (Zip)
 4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
 6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  10/26/2020    M(1)    1110  A $7.80  2410  D   
Common Stock  10/26/2020    M(1)    1770  A $6.55  4180  D   
Common Stock  10/26/2020    S(1)    618  D $49.11 (2) 3562  D   
Common Stock  10/26/2020    S(1)    2262  D $49.96 (3) 1300  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)  $7.80  10/26/2020    M (1)       1110    (4) 4/23/2029  Common Stock  1110  $0.00  35035  D   
Stock Option (Right to Buy)  $6.55  10/26/2020    M (1)       1770    (5) 4/24/2028  Common Stock  1770  $0.00  30105  D   

Explanation of Responses:
(1)  The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.
(2)  The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $48.64 to 49.36, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
(3)  The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $49.41 to 50.39, inclusive.
(4)  The options vested with respect to 1/4 of such shares on April 23, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
(5)  The options vested with respect to 1/4 of such shares on March 12, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Taylor Stacy L
C/O ADAPTIVE BIOTECHNOLOGIES
1551 EASTLAKE AVE E STE 200
SEATTLE, WA 98102

SVP and General Counsel

Signatures
/s/ Stacy L. Taylor by Eric Billings as attorney-in-fact 10/28/2020
**Signature of Reporting Person Date